<DOC>
	<DOCNO>NCT01492400</DOCNO>
	<brief_summary>This study compare safety efficacy 700 ug dexamethasone intravitreal implant ranibizumab 0.5 mg intravitreal injection patient diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Safety Efficacy Study Dexamethasone Versus Ranibizumab Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis type 1 2 diabetes mellitus Diagnosis macular edema Visual acuity 20/200 20/40 Eye surgery study eye within 3 month Use Ozurdex® within 9 month Any active ocular inflammation infection Diagnosis glaucoma Use antiVEGF treatment ( e.g. , Lucentis® ) within 3 month eye systemic use ( e.g. , Avastin® ) within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>